# Addressing antimicrobial resistance in fragile

# and conflict-affected situations Policy brief World Health Organization

Eastern Mediterranean Region

Addressing antimicrobial resistance in fragile and conflict-affected situations: policy brief.

**Print ISBN:** 978-92-9274-745-9 **Web ISBN:** 978-92-9274-746-6

#### © World Health Organization 2025

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Addressing antimicrobial resistance in fragile and conflict-affected situations: policy brief. Cairo: WHO Regional Office for the Eastern Mediterranean; 2025. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at https://iris.who.int/.

**Sales, rights and licensing.** To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.


**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.





## **Executive summary**

Antimicrobial resistance (AMR) poses a growing threat to global health security, with an estimated 8.22 million deaths predicted to be associated with bacterial AMR globally in 2050, including 1.91 million attributable deaths. It is estimated that in 2021, in the WHO Eastern Mediterranean Region, there were 380 000 deaths associated with bacterial AMR, including 92 800 attributable deaths. The impact of AMR is particularly high in fragile and conflict-affected situations (FCS) where health systems are severely compromised. This policy brief highlights the urgent need to integrate AMR mitigation strategies into humanitarian and development responses in FCS, addressing the unique challenges posed by disrupted health infrastructure, population displacement and limited access to diagnostics, treatment, infection prevention and control (IPC), and water, sanitation and hygiene (WASH).

This policy brief is grounded in the four pillars of the people-centred approach to AMR, as endorsed by the Member States of the World Health Organization (WHO) through resolution WHA77.6 at the Seventy-seventh World Health Assembly in 2024: (1) prevention of infections; (2) access to essential health services; (3) timely, accurate diagnosis; and (4) appropriate, quality-assured treatment. Building on this framework – and informed by expert consultations and field experiences from the WHO Eastern Mediterranean Region – the brief outlines interventions across seven domains: infection prevention, diagnosis, treatment, surveillance, community engagement, primary and mobile care, and the wider determinants of health.

It recommends embedding AMR activities within broader health system strengthening efforts and emergency preparedness and response frameworks and plans, while strategically leveraging global financing mechanisms and integrated approaches across the humanitarian-development-peace continuum. This includes integrating AMR interventions in humanitarian response efforts, long-term development plans, community engagement and peacebuilding initiatives to ensure continuity and resilience in fragile and conflict-affected settings. The brief also calls for increased advocacy, operational guidance tailored to FCS contexts and a strengthened research agenda to support effective AMR mitigation in the most vulnerable environments.

This policy brief is for health sector actors and stakeholders such as ministries of health, United Nations agencies, health and WASH cluster implementing partners and other humanitarian and development actors, including donors and both international and local nongovernmental organizations. While the primary audience is governments, the need to collaborate with authorities in non-government controlled areas is acknowledged, foregrounding the role of the "health cluster", which brings together different actors in leveraging their comparative advantages.

It was developed through a desk review of the literature, expert interviews and stakeholder consultations.

#### Introduction

Antimicrobial resistance (AMR) is among the top global health challenges. Globally, an estimated 4.71 million deaths were associated with bacterial AMR in 2021, including 1.14 million deaths directly attributable to it. This is projected to reach 8.22 million associated deaths and 1.91 million attributable deaths in 2050 (1). In the WHO Eastern Mediterranean Region, there were 380 000 deaths associated with bacterial AMR, including 92 800 attributable deaths, in 2021 and this is projected to reach 752 000 associated and 187 000 attributable deaths by 2050 (1). In 2023, bacterial resistance was most frequent in the Eastern Mediterranean and South-East Asian Regions among all WHO regions, with almost 1 in 3 laboratory-confirmed infections caused by resistant bacteria (2). The situation is of particular concern in fragile and conflict-affected situations (FCS), especially with the increasing number of armed conflicts that fuel the development and spread of AMR (3–6). Health systems in FCS are often weak, disrupted and often overwhelmed with casualties, and are therefore unable to adequately address the additional impact of AMR (4).

Generic, normative guidance is often insufficient in FCS, where health systems face unique constraints and vulnerabilities. Addressing AMR in these contexts requires tailored strategies that reflect the complex realities on the ground (5, 6). Despite growing recognition of AMR as a threat in FCS, implementation of prevention and mitigation activities remains limited – largely due to competing priorities. This policy brief offers action-oriented guidance for integrating AMR mitigation across health programmes, based on a people-centred framework that is responsive to the realities of fragile settings.

### Fragile and conflict-affected situations

There is no universally accepted global definition for FCS. In this policy brief, we adopt the World Bank's definition, where conflict-affected countries are identified based on a threshold number of conflict-related deaths relative to population (7). Fragile settings exhibit systemic conditions of extremely low institutional and governance capacity, which significantly impede the state's ability to function effectively, maintain peace and foster economic and social development (8). By 2030, it is estimated that 59% of the world's extreme poor will live in countries affected by fragility, conflict and violence (9). As of August 2025, 307.8 million people worldwide were in need of humanitarian assistance and protection across 73 countries (10).

In WHO's Eastern Mediterranean Region, the World Bank classifies nine countries as FCS (6). As of September 2025, WHO was responding to 25 graded emergencies in the Region, including 18 at the highest level of severity across 10 complex humanitarian crises. In 2023, around 55% of the world's refugees and 33.7 million people who had been forcibly displaced were from the Region (11), and seven countries in the Region were among the 10 countries ranked lowest according to the World Bank's Political Stability and Absence of Violence/Terrorism index (12). In March 2025, an estimated 110 million people needed urgent assistance, accounting for one third of the global humanitarian burden (13).

# Health care provision in FCS

Health care provision in FCS faces numerous challenges, including insecurity, overload, political instability and fragmented governance. Limited capacity to provide health services outside urban areas, ineffective referral systems for critically ill patients and a lack of infrastructure, including electricity, human resources, equipment, medicines, clean water and sanitation, further exacerbate the situation (14, 15). In some FCS, much of the health care infrastructure has been destroyed or severely compromised due to war or neglect. Additionally, inadequate capacity-building mechanisms and coordination, oversight and monitoring of health services contribute to the challenges. Weak processes for developing and implementing national health policies, non-operational health information systems and insufficient public finance management capacity further hinder effective health care delivery in FCS (16).



#### Increased risk of AMR in FCS

Conflict and large-scale population displacement pose significant risks for infections associated with AMR. Disruption to the delivery of essential health services, including vaccination, poor regulatory systems allowing substandard and falsified medicines, eroded microbiology laboratory capacities, and the unavailability of antibiotics because of supply chain issues resulting from interruption, sanctions and the targeting of pharmaceutical factories, are some of the direct factors (17–20).

Indirect factors and wider determinants of AMR include lack of water, sanitation and hygiene (WASH) services, inadequate sewage systems, environmental contamination from the toxic remnants of war, the destruction of infrastructure, unregulated private and less-than-fully qualified service providers, and disruptions to shelter and livelihoods, as well as food and water shortages, which lead to high rates of malnutrition predisposing populations to infection (21, 22). If not appropriately managed, population displacement and migration to neighbouring countries (23) increases the risk of cross-border spread of infectious diseases, including AMR infections.

One of the leading causes of death from traumatic injuries in FCS is infection with multidrug-resistant pathogens, often resulting from inadequate care during conflicts and disasters (3, 5). Several factors contribute to this problem, including overwhelmed medical personnel, limited resources, lack of access to clean water and appropriate antimicrobials, poor implementation of IPC measures, and challenges in environmental cleaning and the proper reprocessing of medical instruments. Additionally, the persistence of heavy metals from weapons can accelerate the development and spread of AMR (24).

The lack of IPC measures in overcrowded health care facilities leads to health care associated infections and the subsequent spread of AMR within communities affected by malnutrition and chronic conditions (17, 20). This is compounded by an access—excess paradox: while many displaced populations face no access to essential antimicrobials, others are exposed to overuse and misuse—through informal markets, poor-quality or counterfeit drugs, and precautionary "just-in-case" prescribing in overstretched humanitarian clinics. Both extremes accelerate the spread of resistance and highlight the urgent need for stronger, better regulated health systems (4).

## Difficulties in addressing AMR in FCS

The prevailing approach to combating AMR often overlooks the unique challenges faced in FCS, rendering existing strategies ineffective in these contexts. While AMR is acknowledged as a threat in FCS, there has been little focus on implementing adequate AMR prevention and mitigation activities (14). This is largely due to competing priorities, such as responding to communicable disease outbreaks, addressing malnutrition and food security, and managing noncommunicable diseases, as well as the limited evidence available on what works in FCS. Additionally, humanitarian and development efforts in FCS situations often prioritize vertical, short-term health interventions, without considering structural determinants such as social, economic and environmental factors (14). Furthermore, currently recommended AMR mitigation strategies often overlook the political and economic context of FCS, complicating efforts to address AMR effectively.



# Factors that support AMR mitigation activities in FCS

- Several partners deliver health services within the health and WASH cluster frameworks, which means more funding opportunities and technical support.
- Anti-infectives and IPC supplies form a critical component of the Interagency Emergency Health Kits (25).
- Aligning with the humanitarian-development-peace continuum improves the effectiveness and efficiency of service delivery (26).
- The inclusion of AMR in the International Health Regulations (2005) and Joint External Evaluations provides a framework for a national preparedness and response within a One Health approach.
- AMR programmes are eligible for financing from global mechanisms, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Pandemic Fund, which prioritize FCS.

# **Key interventions**

Table 1 provides an overview of the key interventions to address AMR in FCS across the following seven domains: infection prevention, diagnosis, treatment, surveillance, community engagement, primary and mobile care, and the wider determinants of health in line with the people-centred approach to AMR (27). The brief addresses all types of FCS, including local, national and regional emergencies, with a particular focus on fragile and post-conflict settings. However, careful consideration must always be given to the unique conditions of each context and emergency.



Table 1. Key interventions across seven key domains for addressing AMR in FCS

Domains	Interventions	Outcomes
Infection prevention	<ul> <li>FCS-specific IPC minimum requirements and simple mobile-applications for monitoring</li> <li>Integrate safe WASH in health facilities (clean water, waste management, hand hygiene)</li> <li>Tailored IPC/WASH training and standard operating procedures/assessment tools for health care workers and first responders (28)</li> <li>Vaccination for epidemic-prone diseases such as cholera, typhoid, meningitis, measles, rotavirus and Haemophilus influenzae type B</li> </ul>	<ul> <li>Strengthened IPC preparedness, readiness and response</li> <li>Improved vaccination coverage</li> <li>Timely containment of outbreaks</li> <li>Reduced health care associated infections, including health worker/occupational infections</li> </ul>
Diagnosis	<ul> <li>Mobile/field/mini laboratories to conduct culture and antibiotic susceptibility testing (AST)</li> <li>AI-enabled culture and AST reporting such as Antibiogo mobile app (29)</li> <li>Piggybacking diagnostics such as nucleic acid amplification tests (NAAT) for tuberculosis</li> </ul>	<ul><li>Increased access to testing</li><li>Improved understanding of AMR patterns</li></ul>
Treatment	<ul> <li>Align the antibiotics humanitarian response H3 package with the WHO AWaRe book (30, 31)</li> <li>Health cluster to align the antibiotics included in emergency kits with the AWaRe book</li> </ul>	<ul><li>Better compliance with treatment guidelines</li><li>Reduced inappropriate use of antibiotics</li></ul>
Surveillance	<ul> <li>Include multidrug-resistant organisms and health care associated infections in the Early Warning, Alert and Response System (EWARS)</li> <li>Establish AMR sentinel surveillance sites</li> <li>Monitor antimicrobial use in facilities using simple mobile apps-based monitoring tools</li> </ul>	<ul> <li>Improved understanding of AMR epidemiology, and early detection of outbreaks or emerging resistance</li> <li>Improved use of antibiotics</li> </ul>
Community engagement	<ul> <li>Training for community and primary health workers and first responders in:         <ul> <li>vaccinations, hygiene, sanitation, wound care, hand hygiene and other IPC measures</li> <li>appropriate use of antimicrobials and microbial diagnostics</li> <li>avoiding self-medication, and adherence to dosage and duration</li> </ul> </li> <li>Make local voices matter: affected communities and frontline providers must be part of the solution, their insights help tailor and contextualize the interventions and make responses more sustainable</li> </ul>	<ul> <li>Improved information, education, and behavioural change communications</li> <li>Improved community infection prevention practices/ decreased community acquired infections</li> <li>Increased AMR-related competencies among primary health workers</li> <li>Stronger community trust</li> <li>Context-sensitive interventions</li> </ul>
Primary and mobile care	<ul> <li>Integrate a minimum package of activities on IPC/WASH and optimal antimicrobial use into primary health care and mobile humanitarian health services</li> <li>Improve access to and use of formal care: ensure primary health care services for both host communities and displaced populations as part of a continuum of care during humanitarian responses</li> <li>Build quality and inclusive services to restore both use of and trust in formal care</li> </ul>	<ul> <li>Improved service delivery in primary health care</li> <li>Increased use of formal care and more rational antimicrobial practices</li> </ul>
Wider health determinants	<ul> <li>Multisectoral measures to address underlying drivers: WASH, food security, safe housing, waste management and occupational/environmental safety</li> <li>Ensure both high-level and local commitment to address the causes and consequences of armed conflict and displacement through contextualised, multisectoral solutions adapted to different conflict stages and impacts</li> <li>Coordinate One Health approaches linking human, animal and environmental health responses</li> </ul>	<ul> <li>Mitigation of AMR spread through improved living and environmental conditions</li> <li>Healthier populations – both displaced groups and host communities</li> <li>More sustainable and equitable AMR responses, rooted in structural solutions</li> </ul>
En	ablers: stable supply chain, quality-assured medicines, predictable financing including for the h	umanitarian WASH road map 2020–2025 <i>(32)</i>
	Risks: destroyed infrastructure, disrupted electricity and water supply, lack of tech	nical expertise due to death.

Risks: destroyed infrastructure, disrupted electricity and water supply, lack of technical expertise due to death, displacement or migration of health care personnel, safety and security challenges, political sanctions

# Recommended actions for different stakeholders addressing AMR in FCS

- **Civil society:** Increase advocacy for AMR as an imminent threat in FCS to national authorities, United Nations agencies and other humanitarian partners, multilateral and bilateral funding agencies, philanthropies, professional organizations, the private sector, academia and nongovernmental organizations; and ensure accountability from the relevant actors.
- National governments and health cluster partners: Embed AMR mitigation activities across health emergency, universal health coverage, primary care, health systems and other relevant programmes. AMR activities should be incorporated into national health system strengthening plans and emergency preparedness and response plans, and funded through domestic budgets and engagement with development partners such as regional development banks, the World Bank Group and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
- **United Nations agencies, humanitarian actors and donors:** Integrate AMR interventions into health emergency preparedness and response activities and humanitarian relief operations and include AMR in all emergency funding calls.
- **WHO, academics and donors:** Advance the research agenda on AMR, with a particular focus on implementation and operational research in humanitarian settings.
- **WHO and health partners:** Develop tailored IPC guidelines and monitoring tools, antibiotic use guidelines, diagnostic packages, simple mobile applications for monitoring, and training modules for health care workers and first responders.

## **Acknowledgments**

WHO thanks the many individuals who contributed to development of this policy brief.

Engy Hamed (AMR Technical Advisor, WHO Sudan country office) and Muhammed Shaffi Fazaludeen Koya (Medical Officer, AMR and IPC, WHO Regional Office for the Eastern Mediterranean) led the development of the brief, which was overseen by Elizabeth Tayler (former acting Regional Adviser, AMR) and Hala Amer (Regional Adviser, AMR), under the general direction of Rana Hajjeh, (former Director of Programme Management), Yvan J Hutin (former Director, Department of Communicable Diseases), Nevin Wilson (Acting Director, Department of Communicable Diseases) and Benedetta Allegranzi (Director, Department of Communicable Diseases), from the WHO Regional Office for the Eastern Mediterranean.

WHO acknowledges the technical contributions of the following staff and consultants at the WHO Regional Office for the Eastern Mediterranean (in alphabetical order): Ali Ardalan (Regional Adviser, Health System in Emergencies Lab), Lucia Barcellini (Technical Officer, Refugee and Migrant Health), Iman Heweidy (Technical Officer, IPC), Miriam Holm (Technical Officer, Office of the Regional Director), Gary Greg Kuniyoshi (Medical Officer, Health Emergencies), Awad Mataria (Director, UHC/Health Systems), Aalaa Moghith (Consultant, AMR), Thomas Mollet (Programme Manager, Health Emergency Information and Risk Assessment), Tonia Rifai (Technical Officer, Refugee and Migrant Health) and Mohamed Sarhan (Consultant, AMR) and Randa Abu Rabe (AMR/IPC Focal person, WHO Country Office for the occupied Palestinian Territories). The following staff at the WHO headquarters, reviewed the brief: Anand Balachandran (Unit Head, National Action Plans, Department of AMR), April Baller (Team Lead, IPC and WASH, Health Emergencies), Nienke Bruinsma (Senior Technical Officer, Department of AMR).

WHO also acknowledges Anna Farra (AMR Coordinator, Middle East Medical Unit, Médecins Sans Frontiers), Bilal Irfan (Bioethicist, Brigham and Women's Hospital, Harvard Medical School, and University of Michigan), Shamim Mannan (Deputy Director, Infectious Diseases, William J Clinton Foundation) and Carine Naim (AMR Analysis and Advocacy Advisor, Médecins Sans Frontiers) for peer review of the brief. None of the reviewers declared any conflicts of interest.

#### References

- 1. EMR Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050. The Lancet Public Health. 2025 Oct 11;10(11):e955–70. doi:10.1016/S2468-2667(25)00201-4.
- 2. Global antibiotic resistance surveillance report 2025. Geneva: World Health Organization; 2025. (https://www.who.int/publications/i/item/9789240116337, accessed on 11 November 2025).
- 3. Granata G, Petersen E, Capone A, Donati D, Andriolo B, Gross M et al. The impact of armed conflict on the development and global spread of antibiotic resistance: a systematic review. Clin Microbiol Infect. 2024 Jul;30(7):858–865. doi:10.1016/j.cmi.2024.03.029.
- 4. Abbara A, Shortall C, Sullivan R, Zwijnenburg W, Moussally K, Aboshamr R et al. Unravelling the linkages between conflict and antimicrobial resistance. NPJ Antimicrob Resist. 2025 Apr 12;3(1):29. doi:10.1038/s44259-025-00099-y.
- 5. Kumar R, Tanous O, Mills D, Wispelwey B, Asi Y, Hammoudeh W et al. Antimicrobial resistance in a protracted war setting: a review of the literature from Palestine. mSystems. 2025 Jun 17;10(6):e0167924. doi:10.1128/msystems.01679-24.
- 6. Abu Dalal H, Irfan B, Elmanama A. Multidrug-resistant bacteria amid health-system collapse in Gaza. Lancet Infect Dis. 2025 Oct;25(10):1064–1066. doi:10.1016/S1473-3099(25)00467-0.
- 7. Classification of fragile and conflict-affected situations [website]. Washington, DC: World Bank Group; 2024 (https://www.worldbank.org/en/topic/fragilityconflictviolence/brief/classification-of-fragile-and-conflict-affected-situations, accessed 16 June 2024).
- 8. Pursuing development goals amid fragility, conflict, and violence. Washington, DC: World Bank Group; 2024 (https://www.worldbank.org/en/results/2024/01/16/pursuing-development-goals-amid-fragility-conflict-and-violence, accessed 20 July 2025).
- 9. World Poverty Clock [website]. World Data Lab; 2025 (https://worldpoverty.io/, accessed 14 September 2025).
- 10. Global humanitarian overview 2025, August update. New York, NY: United Nations Office for the Coordination of Humanitarian Affairs; 2025 (https://humanitarianaction.info/document/global-humanitarian-overview-2025-monthly-updates/article/august-update-0#page-title, accessed 14 September 2025).
- 11. WHO regional appeal for 2024 [website]. Cairo: WHO Regional Office for the Eastern Mediterranean; 2024 (https://www.emro.who.int/fr/eha/resources-for-partners/who-regional-appeal-for-2024.html, accessed 30 September 2025)
- 12. Political stability and absence of violence/terrorism: percentile rank [online database]. Washington, DC: World Bank Group; 2025 (https://data.worldbank.org/indicator/PV.PER.RNK, accessed 03 November 2025).
- 13. Statement by Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean, at the health emergencies press briefing [website]. Cairo: WHO Regional Office for the Eastern Mediterranean; 2024 (https://www.emro.who.int/media/news/statement-by-who-regional-director-for-the-eastern-mediterranean-at-the-heath-emergencies-press-briefing-18-march.html, accessed 22 September 2025).
- 14. Truppa C, Yaacoub S, Valente M, Celentano G, Ragazzoni L, Saulnier D. Health systems resilience in fragile and conflict-affected settings: a systematic scoping review. Confl Health. 2024 Jan 3;18(1):2. doi:10.1186/s13031-023-00560-7.
- 15. Lin TK, Werner K, Kak M, Herbst CH. Health-care worker retention in post-conflict settings: a systematic literature review. Health Policy Plan. 2023 Jan 6;38(1):109–121. doi:10.1093/heapol/czac090.

- 16. Jowett M, Dale E, Griekspoor A, Kabaniha G, Mataria A, Bertone M et al. Health financing policy and implementation in fragile and conflict-affected settings: a synthesis of evidence and policy recommendations. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/health-financing-policy-and-implementation-in-fragile-and-conflict-affected-settings, accessed 6 April 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 17. Pallett SJC, Boyd SE, O'Shea MK, Martin J, Jenkins DR, Hutley EJ. The contribution of human conflict to the development of antimicrobial resistance. Commun Med (Lond). 2023 Oct 25;3(1):153. doi:10.1038/s43856-023-00386-7.
- 18. Asrade Mekonnen B, Getie Yizengaw M, Chanie Worku M. Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review. J Pharm Policy Pract. 2024 Jul 15;17(1):2375267. doi:10.1080/20523211.2024.2375267.
- 19. Immunization and conflict [webpage]. New York, NY: UNICEF; 2025 (https://www.unicef.org/immunization/immunization-and-conflict, accessed 6 April 2025).
- 20. Haraoui LP, Sparrow A, Sullivan R, Burci GL, Dewachi O, Abu-Sittah G. Armed conflicts and antimicrobial resistance: a deadly convergence. AMR Control. 2019;5:69–73.
- 21. Bolton L. Water infrastructure in fragile and conflict-affected states. Brighton, UK: Institute of Development Studies; 2020 (https://www.washcluster.net/sites/gwc.com/files/2022-01/Water\_infrastructure\_in\_fragile\_and\_conflict-affected\_states.pdf, accessed 1 June 2024).
- 22. Event report: Building resilient WASH systems in fragile contexts, Geneva 12–13 December 2019. Berlin: German WASH Network; 2020 (washnet19\_LE-HDN\_report\_200216\_jr.pdf, accessed 1 June 2024).
- 23. Global trends. Forced displacement in 2022. Copenhagen: UNHCR; 2023 (https://www.unhcr.org/sites/default/files/2023-06/global-trends-report-2022.pdf, accessed 2 June 2024).
- 24. Abou Fayad A, Rizk A, El Sayed S, Kaddoura M, Jawad NK, Al-Attar A et al. Antimicrobial resistance and the Iraq wars: armed conflict as an underinvestigated pathway with growing significance. BMJ Glob Health. 2023 Jan;7(Suppl 8):e010863. doi:10.1136/bmjgh-2022-010863.
- 25. The interagency health kit 2024. Geneva: World Health Organization; 2025 (https://www.who.int/emergencies/emergency-health-kits/interagency-emergency-health-kit-2017, accessed 20 September 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 26. Bridging the divide: a guide to implementing the Humanitarian-Development-Peace Nexus for health. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/351260, accessed 6 April 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 27. People-centred approach to addressing antimicrobial resistance in human health: WHO core package of interventions to support national action plans. Geneva: World Health Organization; 2023 (https://www.who.int/publications/i/item/9789240082496, accessed 6 April 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 28. Water supply, sanitation, and hygiene promotion standards: Sphere standards interactive handbook. Geneva: Sphere Association; 2018 (https://handbook.spherestandards.org/en/sphere/#ch006, accessed 10 November 2025).
- 29. WHO compendium of innovative health technologies for low-resource settings 2024. Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/9789240095212, accessed 12 September 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 30. The WHO AWaRe (access, watch, reserve) antibiotic book. Geneva: World Health Organization; 2022 (https://www.who.int/publications/i/item/9789240062382, accessed 6 April 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 31. Preliminary guidance for a package of high-priority health services for humanitarian response (H3 package). Geneva: World Health Organization; 2024 (https://www.who.int/publications/i/item/9789240089440#, accessed 12 September 2025). Licence: CC BY-NC-SA 3.0 IGO.
- 32. Global WASH Cluster. Delivering humanitarian water, sanitation and hygiene (WASH) at scale, anywhere and anytime: road map for 2020–2025. Geneva: UNICEF; 2020 (https://www.washcluster.net/sites/gwc.com/files/2021-12/RoadMap\_2020-2025.pdf, accessed 12 September 2025).

